Scholarlink

Background <p>Viral transduction is a critical step in the manufacturing of genetically modified T cells for immunotherapies, yet conventional transduction methods suffer from low to medium efficiency, high vector consumption, and limited scalability.</p> Methods <p>To address these challenges, we introduce the Transduction Boosting Device (TransB), an innovative, automated, and closed-system platform designed to enable efficient and scalable gene delivery and overcome the limitations of conventional transduction methods. TransB improves cell-virus interactions by facilitating proximity between target cells and viral vectors.</p> Results <p>TransB demonstrated up to 1-fold decrease in processing time, 3-fold reduction in viral vector consumption, and 0.7-fold increase in transduction efficiency compared to 24—well plate method for donor T cell transduction in studies evaluating its impact on transduction process. Comparison studies transducing T cells from three different donors with Lenti-GFP vectors showed that TransB achieved an average 0.5-fold improvement in transduction efficiencies while maintaining comparable post-transduction cell recovery, viability, growth, and phenotype compared to 24—well plate. Furthermore, TransB delivered consistent performance across two different input cell numbers demonstrating scalability of the process.</p> Conclusion <p>These findings suggest that TransB could significantly shorten the transduction time, reduce the transduction cost and improve the transduction efficiency for manufacturing genetically modified T cell therapies. It shows strong potential as a robust, efficient, and scalable platform to enhance T cell therapy manufacturing and help overcome current manufacturing challenges in the field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing T cell transduction: a novel transduction device for efficient and scalable gene delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月12日

查看全文
  • Kang-Zheng Lee,
  • Tan Dai Nguyen,
  • Dan Liu

摘要

Background

Viral transduction is a critical step in the manufacturing of genetically modified T cells for immunotherapies, yet conventional transduction methods suffer from low to medium efficiency, high vector consumption, and limited scalability.

Methods

To address these challenges, we introduce the Transduction Boosting Device (TransB), an innovative, automated, and closed-system platform designed to enable efficient and scalable gene delivery and overcome the limitations of conventional transduction methods. TransB improves cell-virus interactions by facilitating proximity between target cells and viral vectors.

Results

TransB demonstrated up to 1-fold decrease in processing time, 3-fold reduction in viral vector consumption, and 0.7-fold increase in transduction efficiency compared to 24—well plate method for donor T cell transduction in studies evaluating its impact on transduction process. Comparison studies transducing T cells from three different donors with Lenti-GFP vectors showed that TransB achieved an average 0.5-fold improvement in transduction efficiencies while maintaining comparable post-transduction cell recovery, viability, growth, and phenotype compared to 24—well plate. Furthermore, TransB delivered consistent performance across two different input cell numbers demonstrating scalability of the process.

Conclusion

These findings suggest that TransB could significantly shorten the transduction time, reduce the transduction cost and improve the transduction efficiency for manufacturing genetically modified T cell therapies. It shows strong potential as a robust, efficient, and scalable platform to enhance T cell therapy manufacturing and help overcome current manufacturing challenges in the field.